- IBD
-
Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China
-
Mengqi Chen, Zihan Chen, Jianming Lin, Linxin Liu, Tong Tu, Xiaoling Li, Baili Chen, Yao He, Minhu Chen, Zhirong Zeng, Xiaojun Zhuang
-
Intest Res 2026;24(1):52-63. Published online June 11, 2025
-
DOI: https://doi.org/10.5217/ir.2024.00168
-
-
Abstract
PDF PubReader ePub
- Background/Aims
Ustekinumab (UST) and infliximab (IFX) are both effective in the treatment of perianal fistulizing Crohn’s disease (CD), but limited research has focused on comparing the efficacy of UST versus IFX in this field. This study aimed to compare the effectiveness of UST or IFX in treating perianal fistula of CD patients naive to biological agents in a real-world setting.
Methods A retrospective cohort study included patients with perianal fistulizing CD treated with UST or IFX was conducted to evaluate the rates of luminal and perianal fistula response and remission at 6 months after treatment.
Results Ninety-seven patients (49 UST and 48 IFX) were enrolled. Compared to IFX, UST exhibited significantly higher rates of treatment success (89.8% vs. 50.0%, P< 0.001) and intestinal clinical response (85.7% vs. 68.8%, P= 0.048), but no significant differences in fistula remission, fistula response, fistula closure, intestinal clinical remission, endoscopic remission and endoscopic response was observed. Furthermore, multivariate analyses demonstrated complexity of fistula was conversely associated with fistula remission between the UST and IFX groups. Finally, the rates of disease relapse and operation in the IFX group were higher as compared to the UST group during follow-up.
Conclusions UST may serve as a promising alternative to IFX for the treatment of perianal fistulizing CD.
-
Citations
Citations to this article as recorded by 
- The efficacy of ustekinumab in the management of perianal fistulizing Crohn’s disease
Hee Seok Moon Intestinal Research.2026; 24(1): 1. CrossRef - Advanced Medical Therapies for Perianal Fistulizing Crohn’s Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes
Fares Jamal, Tayo Segun-Omosehin, Taylor Viggiano, Hamza Khan, Alejandro J. Gonzalez, Geoff Thomas, Sandra Elmasry, Talha A. Malik Pharmaceuticals.2026; 19(3): 417. CrossRef - Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn’s Disease: Current Evidence and Future Perspectives
Esteban Fuentes-Valenzuela, Francisco Javier Tarrasó, Belén Botella, Pilar Nos, Isabel Vera, Marisa Iborra Journal of Clinical Medicine.2026; 15(18): 7327. CrossRef
-
8,141
View
-
421
Download
-
3
Crossref
|